Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2006-07-18
2006-07-18
Salimi, Ali R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S204100, C435S006120
Reexamination Certificate
active
07078041
ABSTRACT:
Described is a method of identifying an immunologically active antigen of a virus that attacks skin, as well as a method of enriching a population of lymphocytes for T lymphocytes that are specific to a virus that attacks skin. Also provided are HSV antigens and epitopes that are useful for the prevention and treatment of HSV infection that have been identified via the methods of the invention. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.
REFERENCES:
patent: 4859587 (1989-08-01), Roizman
patent: 6375952 (2002-04-01), Koelle et al.
patent: 6413518 (2002-07-01), Koelle et al.
patent: WO 95/06055 (1995-03-01), None
patent: WO 98/20016 (1998-05-01), None
patent: WO 01/23414 (2001-04-01), None
Fuhlbrigge, Robert C. et al., “Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells”, Nature, Oct. 30, 1997, vol. 389, pp. 978-981.
Khan, Naeem et al., “Comparative Analysis of CD8+ T Cell Responses against Human Cytomegalovirus Proteins pp65 and Immediate Early 1 Shows Similarities in Precursor Frequency, Oligoclonality, and Phenotype”, The Journal of Infectious Diseases, Mar. 2002, vol. 185, pp. 1025-1034.
Marshall, Natalie A. et al., “Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation”, Immunology, Oct. 15, 2000, Blood, vol. 96, No. 8, pp. 2814-2821.
Pober, Jordan S. et al., “Human Endothelial Cell Presentation of Antigen and the Homing of Memory/Effector T Cells to Skin”, Annals New York Academy of Sciences, 2001, vol. 941, pp. 12-25.
Stanberry, Lawrence R. et al., “Prospects for Control of Herpes Simplex Virus Disease through Immunization”, Clinical Infectious Diseases, Mar. 2000, vol. 30, pp. 549-566.
E. De Plaen et al., “Cloning of Genes Coding for Antigens Recognized by Cytolytic T Lymphocytes,” Immunology Methods Manual, 1997, 692-718.
A. Dolan et al., The Genome Sequence of Herpes Simplex Virus Type 2, Journal of Virology, 1998, 72(3):2010-2021.
Koelle et al., “Recognition of Herpes Simplex Virus Type 2 Tegument Proteins by CD4 T Cells . . . ” Jnl. of Virology, 1998, 72(9): 7476-7483.
D.M. Koelle, “The Roles of T Lymphocytes in Host Responses to Herpes Simplex Virus,” Herpes, 1995, 2:83-88.
D.M. Koelle et al., “Clearance of HSV-2 from Recurrent Genital Lesions Correlates with Infiltration of HSV-Specific Cytotoxic T Lymphoctyes,” The Journal of Clinical Investigation, 1998, 101(7):1500-1508.
D.M. Koelle et al., “Preferrential Presentation of Herpes Simplex Virus T-Cell Antigen by HLA DQA1*0501/DQB1*0201 in Comparison to HLA DQA1*0201/DQB1*0201,” Human Immunology, 1997, 53(2):195-205.
D.M. Koelle et al., “Direct Recovery of Herpes Simplex Virus (HSV)-Specific T Lymphocyte Clones from Recurrent Genital HSV-2 Lesions,” The Journal of Infectious Diseases, 1994, 169:956-61.
D.M. Koelle et al., “Antigenic Specificities of Human CD+T-Cell Clones Recovered from Recurrent Genital Herpes Simples Virus Type 2 Lesions,” Journal of Virology, 1994, 68(5):2803-2810.
W.W. Kwok et al., “Peptide Binding Affinity and pH Variation Establish Functional Thresholds for Activation of HLA-DQ-Restricted T Cell Recognition,” Human Immunology, 1999, 60(7):619-626.
Paoletti, “Applications of Pox Virus Vectors to Vaccination: An Update,” Proceedings of the National Academy of Science USA, Oct. 1996, 93:11349-11353.
C.M. Posavad et al., “High Frequency of CD8+Cytotoxic T-Lymphoctye Precursors Specific for Herpes Simplex Viruses in Persons with Genital Herpes,” Journal of Virology, 1996, 70(11):8165-8168.
S. Reichstetter et al., “MCH-Peptide Ligand Interactions Establish a Functional Threshold for Antigen-Specific T Cell Recognition,” Human Immunology, 1999, 60(7):608-618.
B. Roizman et al., “Herpes Simplex Viruses and Their Replication”, Fundamental Virology, 2ndEdition, ed. Fields et al, Raven Press, 1991, New York, pp. 849-895.
Stanberry, “Glycoprotein-D-Adjuvant Vaccine to Prevent Genital Herpes,” N. Engl. J. Med., 2002, 347(21):1652-1661.
M.A. Tigges et al., “Human CD8+Herpes Simplex Virus-Specific Cytotoxic T-Lymphocyte Clones Recognize Diverse Virion Protein Antigens,” Journal of Virology, 1992, 66(3):1622-1634.
Williams et al., “Characterization of a Herpes Simplex Virus Type 2 Deoxyuridine . . . ” Virology, 1987, 156:282-292.
Williams, “Deoxyuridine Triphosphate Nucleotidohydrolase Induced by Herpes Simplex Virus Type 1,” Jnl. of Biological Chemistry, 1984, 259(16): 10080-10084.
Corey Lawrence
Koelle David M.
Liu Zhi
Canady Karen S.
Canady & Lortz
Salimi Ali R.
University of Washington
LandOfFree
Rapid, efficient purification of HSV-specific T-lymphocytes... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Rapid, efficient purification of HSV-specific T-lymphocytes..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Rapid, efficient purification of HSV-specific T-lymphocytes... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3579417